Privia Health (PRVA) analyst forecast and price target
Analyst forecast
Consensus of 19 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Equal-Weight | $24.00 from $25.00 | May 26, 2026 |
| Canaccord Genuity | Maintained | Buy | $34.00 from $35.00 | May 8, 2026 |
| Evercore ISI Group | Maintained | Outperform | $26.00 from $30.00 | Apr 8, 2026 |
| Barclays | Maintained | Equal-Weight | $25.00 from $23.00 | Mar 25, 2026 |
| Citigroup | Maintained | Buy | $32.00 from $34.00 | Mar 3, 2026 |
| Truist Securities | Maintained | Buy | $33.00 from $31.00 | Mar 2, 2026 |
| Canaccord Genuity | Maintained | Buy | $35.00 from $34.00 | Feb 27, 2026 |
| RBC Capital | Maintained | Outperform | $31.00 | Jan 9, 2026 |
| Stephens & Co. | Maintained | Overweight | $32.00 | Dec 4, 2025 |
| JP Morgan | Maintained | Overweight | $33.00 from $32.00 | Nov 13, 2025 |
| BMO Capital | Initiated Coverage | Outperform | $30.00 | Nov 13, 2025 |
| Canaccord Genuity | Maintained | Buy | $34.00 from $32.00 | Nov 12, 2025 |
| Truist Securities | Maintained | Buy | $31.00 from $30.00 | Nov 10, 2025 |
| Barclays | Maintained | Equal-Weight | $23.00 from $22.00 | Nov 10, 2025 |
| Evercore ISI Group | Maintained | Outperform | $30.00 from $28.00 | Nov 7, 2025 |
| Citizens | Maintained | Market Outperform | $31.00 from $30.00 | Nov 7, 2025 |
| Barclays | Maintained | Equal-Weight | $22.00 from $21.00 | Oct 9, 2025 |
| Stephens & Co. | Maintained | Overweight | $32.00 | Sep 24, 2025 |
| Stephens & Co. | Maintained | Overweight | $32.00 | Sep 4, 2025 |
| JMP Securities | Maintained | Market Outperform | $30.00 from $29.00 | Aug 29, 2025 |
Frequently asked questions
Is PRVA a buy, sell, or hold?
Analysts covering Privia Health currently average a Buy rating: 18 buy, 1 hold and 0 sell, from 19 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on PRVA?
On May 26, 2026, Barclays maintained Privia Health at Equal-Weight with a price target of $24.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.